Strides Pharma Science cash flow

Latest FY26

Cash from operations: ₹703cr+2.7% on FY25
Capital spending: ₹423cr+74.4% on FY25
Free cash flow: ₹280cr−36.7% on FY25
Cash from financing: −₹453cr−₹643 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	202	192	221	243
	—	−2.8	1.1	0.0	0.0
	—	179	249	314	261
	—	0.0	0.0	−30.4	−74.5
	—	−40.5	−48.0	0.0	0.0
	—	0.0	−102	0.0	0.0
	—	0.3	1.6	1.6	1.3
	—	−40.8	13.6	20.9	−28.5
	—	−107	−9.3	158	−25.1
	—	−1.3	−2.1	−5.7	4.3
	—	−285	−217	30.7	−8.1
	—	−109	−51.6	39.1	−347
	—	311	105	−149	−102
	—	0.0	0.0	17.5	33.6
Cash from operating activities
	743	668	485	58.8	−0.9
	—	105	132	618	−42.3
	—	774	617	677	−43.2
	—	71.1	−67.0	−24.2	−87.6
	—	703	684	701	44.4
Cash from investing activities
	—	423	242	118	94.9
	—	119	68.1	88.8	7.3
	—	92.2	41.5	0.0	0.0
	—	0.0	0.0	15.1	106
	—	0.0	0.0	54.2	0.0
	—	4.6	13.3	0.0	0.0
	—	0.0	0.0	15.3	6.9
	—	33.9	29.8	−66.9	489
	—	−173	−89.7	−150	302
Cash from financing activities
	—	0.4	6.1	1.4	1.4
	—	0.0	0.0	51.3	37.1
	—	171	171	350	330
	—	383	764	734	305
	—	36.7	33.4	55.8	53.1
	—	168	0.0	292	224
	—	36.9	23.0	13.5	0.0
	—	−453	−643	−693	−214
	—	76.1	−47.9	−143	133
	—	0.1	−0.5	0.0	−0.2
	—	76.1	−48.4	−142	133
	—	189	113	161	304
Reference items
	956	925	803	743	430
	18.3%	19.0%	17.6%	18.4%	11.7%
	280	280	442	583	−50.5
	—	−15.3	—	−69.2	—
	₹30.33	₹30.33	₹47.94	₹63.24	−₹5.48
	33.00×	—	—	—	—
	—	1.22×	0.19×	−7.43×	−0.21×
	—	71.1	−67.0	−24.2	−87.6
	—	168	—	292	224

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

STAR₹1,001.10

Strides Pharma Science Ltd.

· Pharma & Health

₹ CrorePeersSPARC SUPRIYA SHILPAMED THYROCARE RUBICON VIYASH YATHARTH PARKHOSPSMcap ₹9,227 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	243.3	220.7	192.3	202.4	—
+ Impairment Loss / (Reversal)	0.0	0.0	1.1	-2.8	—
+ Finance Costs	261.1	314.4	248.9	178.5	—
+ Interest Income	-74.5	-30.4	0.0	0.0	—
+ Dividend Income	0.0	0.0	-48.0	-40.5	—
+ Fair Value (Gains) / Losses	0.0	0.0	-102.1	0.0	—
+ Share-based Payments	1.3	1.6	1.6	0.3	—
+ Unrealised FX (Gain) / Loss	-28.5	20.9	13.6	-40.8	—
+ Other Non-cash Items	-25.1	157.8	-9.3	-107.3	—
+ Other — Cash Effects are Investing / Financing	4.3	-5.7	-2.1	-1.3	—
Changes in Working Capital
+ Inventories	-8.1	30.7	-217.0	-284.5	—
+ Trade Receivables — Current	-347.4	39.1	-51.6	-109.3	—
+ Trade Payables — Current	-102.3	-148.5	104.9	310.7	—
+ Provisions — Current	33.6	17.5	0.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	-0.9	58.8	485.1	668.2	742.5
+ Total Adjustments (incl. Working Capital)	-42.3	618.0	132.3	105.4	—
Cash from Operations (pre-tax)	-43.2	676.8	617.3	773.6	—
+ Income Taxes Paid	-87.6	-24.2	-67.0	71.1	—
Cash from Operating Activities	44.4	701.1	684.4	702.5	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	94.9	118.2	242.5	422.9	—
+ Disp of Fixed Assets	7.3	88.8	68.1	119.3	—
+ Disp of Other Long-term Assets	0.0	0.0	41.5	92.2	—
+ Purchase of Investments (Equity / Debt)	106.2	15.1	0.0	0.0	—
+ Loans & Advances Made	0.0	54.2	0.0	0.0	—
+ Dividends Received — Investing	0.0	0.0	13.3	4.6	—
+ Interest Received — Investing	6.9	15.3	0.0	0.0	—
+ Other Inflows / (Outflows) — Investing	489.5	-66.9	29.8	33.9	—
Cash from Investing Activities	302.5	-150.3	-89.7	-173.0	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	1.4	1.4	6.1	0.4	—
+ Proceeds from Other Equity Instruments	37.1	51.3	0.0	0.0	—
+ Proceeds from Borrowings	330.4	349.8	171.4	170.5	—
+ Repayment of Borrowings	305.5	734.2	763.7	382.8	—
+ Payment of Lease Liabilities	53.1	55.8	33.4	36.7	—
+ Interest Paid	224.2	292.2	0.0	167.9	—
+ Dividends Paid	0.0	13.5	23.0	36.9	—
Cash from Financing Activities	-213.9	-693.3	-642.6	-453.4	—
Net Changes in Cash (pre-FX)	133.0	-142.5	-47.9	76.1	—
+ Effect of FX Rate Changes on Cash	-0.2	0.0	-0.5	0.1	—
Net Changes in Cash	132.8	-142.5	-48.4	76.1	—
Closing Cash	303.5	161.0	112.6	188.7	—
Reference Items
EBITDA	430.2	743.3	802.8	925.3	956.3
EBITDA Margin %	11.66	18.35	17.58	19.04	18.34
Free Cash Flow (CFO − Capex)	-50.5	582.9	441.9	279.6	279.6
Free Cash Flow to Equity	—	-69.2	—	-15.3	—
Free Cash Flow per Basic Share	-5.48	63.24	47.94	30.33	30.33
Price to Free Cash Flow	—	—	—	—	33.00
Cash Flow to Net Income	-0.21	-7.43	0.19	1.22	—
Cash Paid for Taxes	-87.6	-24.2	-67.0	71.1	—
Cash Paid for Interest	224.2	292.2	—	167.9	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.